AstraZeneca PLC (NASDAQ:AZN) Shares Sold by GLOBALT Investments LLC GA

GLOBALT Investments LLC GA reduced its holdings in AstraZeneca PLC (NASDAQ:AZN) by 3.8% during the 3rd quarter, Holdings Channel reports. The fund owned 69,485 shares of the company’s stock after selling 2,747 shares during the period. GLOBALT Investments LLC GA’s holdings in AstraZeneca were worth $5,414,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Price T Rowe Associates Inc. MD raised its position in AstraZeneca by 17.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 61,271,974 shares of the company’s stock valued at $4,151,177,000 after acquiring an additional 9,002,450 shares in the last quarter. Swedbank AB purchased a new position in AstraZeneca in the first quarter valued at $186,127,000. Manning & Napier Advisors LLC purchased a new stake in shares of AstraZeneca during the 2nd quarter worth about $188,476,000. Hsbc Holdings PLC grew its position in shares of AstraZeneca by 750.3% during the 2nd quarter. Hsbc Holdings PLC now owns 1,283,274 shares of the company’s stock valued at $100,523,000 after acquiring an additional 1,132,362 shares during the period. Finally, Farallon Capital Management LLC grew its position in shares of AstraZeneca by 65.1% during the 2nd quarter. Farallon Capital Management LLC now owns 2,409,718 shares of the company’s stock valued at $187,934,000 after acquiring an additional 950,000 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Price Performance

AZN stock opened at $63.23 on Monday. AstraZeneca PLC has a 1 year low of $60.47 and a 1 year high of $87.68. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. The firm has a market capitalization of $196.05 billion, a PE ratio of 30.25, a price-to-earnings-growth ratio of 1.17 and a beta of 0.47. The business has a 50 day simple moving average of $75.03 and a 200-day simple moving average of $78.23.

AstraZeneca (NASDAQ:AZN) last issued its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. The business had revenue of $13.57 billion during the quarter, compared to the consensus estimate of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The company’s revenue for the quarter was up 18.0% on a year-over-year basis. During the same period last year, the company earned $0.87 EPS. Equities research analysts anticipate that AstraZeneca PLC will post 4.07 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have commented on the company. TD Cowen raised their price objective on AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a report on Monday, August 12th. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Finally, Erste Group Bank raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.